- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04695301
Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation
February 10, 2022 updated by: Hospital Israelita Albert Einstein
COVID-19, an acute respiratory disease caused by coronavirus-2 (SARS-CoV-2), and in most cases, causes mild to moderate symptoms of fever, cough and dyspnea.
However, a not insignificant portion, given the total number of people affected, will present symptoms of severe acute respiratory failure and multiple organ failure, requiring hospitalization under intensive care, use of mechanical ventilation, prolonged period of immobilization and, consequently, physical, cognitive and psychological damage, which may affect survivors for a long period after hospitalization.
All of these factors are known to have an impact on various areas of life: personal, social and economic, which makes the need for continued specific care after hospital discharge relevant.
In this context, the role of rehabilitation programs is fundamental, aiming not only at a safer dehospitalization, but also at the continuity of care with the objective of restoring the biopsychosocial skills of these individuals, allowing functional independence for activities of daily life and a shorter return physical and social activities performed before the disease.
However, the big challenge for the health system is how to offer this on a large scale.
Therefore, knowing the clinical and functional profile of these patients at discharge and verifying the viability of a digital platform for rehabilitation and monitoring of these patients is the first step to allow the creation of a new form of continuity of care and access to affected patients with serious diseases such as COVID-19 and other syndromes capable of generate functional impairment.
Therefore,the investigators objective is to characterize and monitor the functional profile and exercise capacity of patients affected by COVID-19 at the hospital discharge, as well as to verify the viability and compliance of patients to the use of a digital platform for the application of a distance rehabilitation program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The investigators proposal is to characterize and evaluate the impact of the disease on the clinical, functional and social aspects in these patients affected by COVID-19 and to propose the continuity of specific care after hospital discharge with a physical rehabilitation program through a digital platform, remotely for a period of 3 months.
The proposed hypothesis is that patients convalescing from COVID-19 and undergoing the rehabilitation program will have a gain in functional skills and quality of life.
The professional team involved in this study will be responsible for managing, monitoring and evaluating the participating patients and monitoring the performance of the proposed functional exercises.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
São Paulo, Brazil, 05652-000
- Instituto Israelita de Ensino e Pesquisa Albert Einstein 's (IIEP)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women affected by COVID-19
- over 18 years of age, admitted to HIAE partner hospitals
Exclusion Criteria:
- presence of a physical or cognitive condition that makes it impossible or contraindicated to perform the 2-minute stride test and perform the proposed exercises.
- Patients with a more severe clinical and functional profile,
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: digital platform rehabilitation
Rehabilitation program through a digital platform for 3 months
|
During 3 months the patients will participate in a rehabilitation program through a digital platform
|
Experimental: control group
Patients without access to technology will do the exercises using booklets and will compose the control group
|
During 3 months the patients will participate in a rehabilitation program through a digital platform
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize the clinical function profile of patients affected by COVID-19
Time Frame: 3 months
|
Characterize the clinical functional profile of patients affected by COVID-19 by data from medical records
|
3 months
|
Characterize the exercise capacity of patients affected by COVID-19
Time Frame: 3 months
|
Characterize the exercise capacity of patients affected by COVID-19 by 2-minute step test
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess clinical and demographic data
Time Frame: 3 months
|
Assess clinical and demographic data
|
3 months
|
Assess functional level at hospital discharge
Time Frame: 3 months
|
Assess functional level at hospital discharge and 3 months after discharge by physical test
|
3 months
|
Assess patient compliance of the rehabilitation program using the digital platform
Time Frame: 3 months
|
Assess patient compliance of the rehabilitation program using the digital platform checking your adherence to the program
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Luciana D Matos, MD,PhD, Hospital Israelita Albert Einstein
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2020
Primary Completion (Actual)
July 1, 2021
Study Completion (Actual)
October 1, 2021
Study Registration Dates
First Submitted
December 29, 2020
First Submitted That Met QC Criteria
January 4, 2021
First Posted (Actual)
January 5, 2021
Study Record Updates
Last Update Posted (Actual)
February 11, 2022
Last Update Submitted That Met QC Criteria
February 10, 2022
Last Verified
July 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 34170820.0.1001.0071
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
all IPD that underlie results in a publication
IPD Sharing Time Frame
when to published
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infections
-
Salvacion USA Inc.Completed
-
Janssen Vaccines & Prevention B.V.Completed
-
Beijing Ditan HospitalUnknown
-
Qilu Hospital of Shandong UniversityRecruitingCoronavirus | Traditional Chinese MedicineChina
-
CHU de ReimsCompletedCORONAVIRUS INFECTIONSFrance
-
NPO PetrovaxCompletedInfections, CoronavirusBelarus, Russian Federation
-
Texas A&M UniversityM.D. Anderson Cancer Center; Baylor College of Medicine; Cedars-Sinai Medical... and other collaboratorsActive, not recruitingCoronavirus Infection | Coronavirus | Coronavirus as the Cause of Diseases Classified ElsewhereUnited States
-
Maimonides Medical CenterTerminatedCOVID, CoronavirusUnited States
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
Bursa Yüksek İhtisas Education and Research HospitalUnknownCoronavirus as the Cause of Diseases Classified ElsewhereTurkey
Clinical Trials on Rehabilitation protocol through a digital platform
-
Universidad Peruana Cayetano HerediaNational Institutes of Health (NIH)UnknownEffect of Problem-solving Therapy Offered Through a Web Platform on Levels of Stress (PST on stress)Stress, Psychological | Occupational Stress | Mental Health Wellness 1 | BehaviorPeru
-
University of ValenciaMinisterio de Ciencia e Innovación, SpainRecruitingIntervention on Socio-emotional Development and Well-being Through ICTs in Early Adulthood (EMOWELL)Emotion RegulationSpain
-
Schön Klinik Berchtesgadener LandBavarian State Ministry of Health and Care (Funding); Betriebskrankenkassen... and other collaboratorsRecruitingPost-COVID-19 SyndromeGermany
-
Sword Health, SACentro Hospitalar e Universitário do PortoWithdrawnHome-based Exercise Rehabilitation With a Novel Digital Biofeedback System for Chronic Low Back PainNon-specific Chronic Low Back PainPortugal
-
Istituto Nazionale di Ricovero e Cura per AnzianiMinistero dell'Università e della Ricerca, ItaliaRecruiting
-
Sword Health, SAHospital da PreladaCompletedKnee Osteoarthritis | Arthropathy of KneePortugal
-
Universidad Francisco de VitoriaHospital Beata María AnaCompleted
-
Selda SarıkayaZonguldak Bulent Ecevit UniversityCompletedCOVID-19 | COVID-19 PneumoniaTurkey
-
MTI UniversityEnrolling by invitationSpastic Diplegic Cerebral PalsyEgypt
-
University Hospital, Basel, SwitzerlandWyeth is now a wholly owned subsidiary of PfizerCompletedChronic Kidney Disease | Kidney TransplantationSwitzerland